Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.54 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943224 | 0.80 | NAMPT (0.84) | NAMPT | |
| SCHEMBL24042554 | 0.80 | NAMPT (0.84) | NAMPT | |
| SCHEMBL23320444 | 0.71 | NAMPT (1.00) | NAMPTPRMT3KMT2ARAB9A | |
| SCHEMBL23320516 | 0.69 | NAMPT (0.82) | NAMPTPRMT3 | |
| SCHEMBL23320512 | 0.60 | NAMPT (0.74) | NAMPTRAB9A | |
| SCHEMBL23320477 | 0.59 | NAMPT (0.60) | NAMPTPRMT3MEN1KMT2ANPC1 | |
| SCHEMBL13545811 | 0.58 | LMNA (0.57) | KMT2ANPC1MAPTRAB9A | |
| SCHEMBL20229888 | 0.57 | POLB (0.49) | NAMPTMEN1KMT2ABCHEACHE | |
| SCHEMBL25138742 | 0.56 | HDAC1 (0.71) | MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL1004019 | 0.56 | HDAC1 (0.71) | MEN1KMT2AMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, ABAT | NAMPT 1/4885PRMT3 246/4885MEN1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.